🇺🇸 Moxonidine (Physiotens) in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Window: 22 April 2025 – 22 April 2026
Total reports: 4

Most-reported reactions

Fibrosis — 1 report (25%)
Nephrogenic Fibrosing Dermopathy — 1 report (25%)
Skin Fibrosis — 1 report (25%)
Thrombophlebitis — 1 report (25%)

Source database →

Other Cardiovascular approved in United States

Frequently asked questions

Is Moxonidine (Physiotens) approved in United States?

Moxonidine (Physiotens) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Moxonidine (Physiotens) in United States?

Baker Heart and Diabetes Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.